For immediate release

New combination therapy using intuitive inhaler available for the treatment of COPD and asthma in UK

Innovative Spiromax® technology designed to address some of the common problems people experience with their current treatment

HARLOW. 2nd September 2014. Teva UK Limited announced today, that their innovative new inhaler DuoResp Spiromax® (budesonide/formoterol) is now available in the UK. It is licensed for the treatment of patients aged 18 or over with asthma or chronic obstructive pulmonary disease (COPD) where use of a combination of inhaled corticosteroid and long-acting beta₂-adrenoceptor agonist is appropriate.

DuoResp Spiromax® is a new multi-dose dry-powder inhaler containing a Fixed Dose Combination (FDC) of budesonide, an inhaled corticosteroid used to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta₂ agonist used to relieve bronchoconstriction in patients with asthma or COPD.

It is estimated that 5.4 million people in the UK are living with asthma which costs the NHS around £1 billion a year and was the cause of 1,167 deaths in the UK in 2011. An estimated 75% of hospital admissions for asthma are avoidable and as many as 90% of the deaths from asthma are preventable.¹

COPD is thought to affect 3.7 million people in the UK, although only 900,000 have been diagnosed.² It is the second largest cause of emergency hospital admission in the UK, with 130,000 emergency admissions every year, and is the fifth most common cause of death in England and Wales.³

Inhaled therapy with fixed dose combinations of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) is an important step in achieving asthma and COPD control for patients. However a substantial percentage of people who use inhalers worldwide have inadequate inhaler technique and this is associated with reduced disease control⁴. Despite this well-documented issue, appropriate use of inhalers does not seem to have improved significantly.⁵
"The approval and launch of DuoResp Spiromax® is welcome news for both patients and healthcare professionals. The intuitive Spiromax® inhaler device aids simpler inhaler technique. This in turn has the potential to improve asthma and COPD management and control." commented Dr Kevin Gruffydd-Jones, GP Principal, Box, Wiltshire.

Two phase IIIIB trials in patients in the UK with persistent asthma to compare DuoResp® Spiromax® vs. an alternative approved Budesonide/Formoterol Multi-dose Dry Powder Inhaler have been initiated. The first has recently been completed and is currently being evaluated. The second trial is ongoing. Both studies are expected to report late 2014 or early 2015.

DuoResp Spiromax® received marketing authorisation from the European Commission on the 29th of April 2014.

###

For more information contact Teva UK Limited on 01977 628500, or email general.enquiries@tevauk.com.

To find out more about Teva UK Limited, visit www.tevauk.com.

- ENDS -

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

Notes to Editors:

About Teva UK Limited
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory, CNS and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s Specialty Medicines businesses focus on CNS, respiratory oncology, pain, and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our innovative products, especially COPAXONE® (including competition from orally-administered alternatives, as well as from potential purported generic equivalents); the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from the research and development efforts invested in our pipeline of specialty and other products; our ability to reduce operating expenses to the extent and during the timeframe intended by our cost reduction program; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; our
potential exposure to product liability claims that are not covered by insurance; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; uncertainties related to our recent management changes; the effects of increased leverage and our resulting reliance on access to the capital markets; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; the impact of continuing consolidation of our distributors and customers; significant impairment charges relating to intangible assets and goodwill; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2013 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

References:

6. Rychlik R & Kreimendahl F. Incremental innovation in asthma/COPD management. Abstract presented at IPCRG 2014